Case File
efta-efta01196657DOJ Data Set 9OtherDS9 Document EFTA01196657
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01196657
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
GIO
GLOBAL INVESTMENT
OPPORTUNITIES
GIO Market Alert
March 2015
Increasingly the market appears to be coming around to our view that not only is the Fed likely to hike in 2015 but the timing of
that hike is likely to be in the next 3-6 months (i.e. June or September). While we view this as a positive sign and affirmation that
the US economy is solidly expanding, equity markets can be choppy in the months around the beginning of a tightening cycle as
markets digest the news. Looking back 30 years, the S&P 500 has typically been rangebound in the months before the first Fed
hike with peak-to-trough drawdowns ranging from 5-10%. Furthermore, our views on continued US dollar strength and oil
weakness as it re-tests recent lows could drive additional concerns on corporate earnings. With this in mind, we think it is prudent
to take profits on some of our US equity exposure which has done well over the last 3 years to take down risk in the US. We will
look for the right opportunity to reinvest this dry powder when market volatility increases.
WHERE TO TAKE PROFITS
Large Cap Outperformers
There are many companies that have outperformed in the last
6-9 months and as a result now have a smaller valuation
cushion. We would take profits on those outperformers,
particularly those up over 10% in 2015 in the large cap
technology and pharma sectors that lack catalysts in the next 3-
6 months. We expect to buy them back on a —10% pullback.
Payments Innovation
Since the announcement of Apple Pay in September 2014, the
stocks we highlighted as beneficiaries of mobile payments
innovation are up 14% due to strong results and underlying
trends. While we still like many of the companies longer term,
the credit card networks and NFC chip makers may become
more volatile in the near term.
Life Sciences
Last year we highlighted an opportunity in Life Sciences,
particularly those focusing on genetic testing. While we still like
some companies longer term, we believe the primary catalyst
around reduced sequencing costs has played out in the near
term and are taking profits on the stock basket up 12% since
inception in February 2014 with some individual stocks up over
30%. For clients interested in maintaining exposure to the
theme, we would focus on hardware manufacturers.
WHAT WE'RE HOLDING ON TO
Hedged European Equities and Short EUR
With the ECB engaging in quantitative easing (QE) we think the
pressure remains for euro to continue weakening and may last
well below parity. We expect European equities to remain
supported with investors following the US QE playbook. While
European equities could experience some volatility, it could be
tempered by continued investor flows.
Hedged Japanese Equities
Recent improvements in Japanese macro fundamentals keep us
invested in Japanese equities. There may also be potential
catalysts around an equity-geared increase in QE and flows
benefits from continued shifts into equities by asset allocators
following the GNPs lead.
US Banks
While recognizing that US bank stocks will not be fully immune
to market beta, as a sector bank valuations remain low in a
historical context and capital returns to shareholders seem to
be increasing following the recent CCAR (Comprehensive
Capital Analysis and Review) results. Furthermore, the sector
should broadly benefit from Fed hikes and as a result we would
maintain exposure to this sector, especially to the regional
banks, even through near term volatility.
Anton Pil
Jeanne Sun
Peter Epstein
Investment products: Not FDIC insured • No bank guarantee • May lose value
EFTA01196657
GIO
GLOBAL. INVESTMENT
OPPORTUNITIES
IMPORTANT INFORMATION
This presentation and the material contained herein is not a product of the J.P. Morgan Research Department and is not a research report, although it may refer to a
research report or research analyst. This presentation should be reviewed in conjunction with U.S. research published by.I.P. Morgan Securities, LLC to the extent
that such research exists. The opinions and ideas expressed herein do not take into account individual client circumstances, objectives and needs. Transactions in
any securities that may be referenced herein may not be suitable for all investors.
This presentation has been prepared for information purposes only. Nothing in this material is intended to be a solicitation for any product or service offered by.I.P.
Morgan's Private Bank or any of its affiliates. Information contained herein has been obtained from sources believed to be reliable but we do not guarantee its
accuracy or completeness and accept no responsibility for any direct or consequential losses arising from its use. The views and strategies described herein may not
be suitable for all investors. This information is not intended as an offer or solicitation for the purchase or sale of any financial instrument and is being provided
merely to illustrate a particular investment strategy.
Past performance is no guarantee of future result.
This material contains certain information/statistics that hove been obtained from sources deemed reliable, but J.P. Morgan Securities does not guarantee their
accuracy or completeness. Past performance is not a guarantee of future results, and information is subject to change at any time.
Bank products and services are offered through JPMorgan Chase Bank, NA. and its affiliates. Securities are offered by.I.P. Morgan Securities LLC and Clearing and
Custody by 1.P. Morgan Clearing Corp., both are members of FINRA, NYSE and SIPC.J.P. Morgan Securities LLC and J.P. Morgan Clearing Corp are affiliates of
JPMorgan Chase Bank, N.A.
Investment products: Not FDIC insured • No bank guarantee • May lose value
EFTA01196658
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
SWIFT/BIC
INFORMATIONWire Ref
referencedForum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.